CClinicalTrials.gg
Not yet recruitingNCT06570837Updated Aug 26, 2024

Iron Deficincy Among Children With type1 DM in Assiut University Hospital

An observational study in Iron Deficiency, Anaemia in Children Type1DM, sponsored by Assiut University. Not yet recruiting. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
141
Ages
6 Years to 12 Years
Sex
All
01

Study summary

detect the prevelance of anemic and non anemic iron deficiency in children with type 1 diabetes.assess the impact of anemic and non anemic iron deficiency in children with type 1 diabetes on their general condition

Read the detailed description

Anemic and non anemic iron deficiency : is a global public health problem affecting both developing and developed countries with major consequences for human health as well as social and economic development.Iron deficiency anemia (IDA) appears to be more common in diabetic patients compared to non-diabetic population ,Iron deficiency (ID) and IDA can impair glucose homeostasis in human and may negatively affect glycemic control and predispose to more complications in diabetic patients. On the other hand diabetes and its complications are associated with anemia and its correction improves diabetes control and may prevent or delay the occurrence of complications. (1) Iron-deficiency anemia is the most common type of anemia. It occurs when your body doesn't have enough iron, which your body needs to make hemoglobin. When there isn't enough iron in your blood, the rest of your body can't get the amount of oxygen it needs.(2) Iron-deficiency anemia may be present without a person experiencing symptoms. (3) It tends to develop slowly; therefore the body has time to adapt, and the disease often goes unrecognized for some time. (4) If symptoms present, patients may present with the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes),(5) and the symptoms of feeling tired, weak, dizziness, lightheadedness, poor physical exertion, headaches, decreased ability to concentrate, cold hands and feet, cold sensitivity, increased thirst and confusion. (6)(7) None of these symptoms (or any of the others below) are sensitive or specific. In severe cases, shortness of breath can occur. (8) Pica may also develop; of which consumption of ice, known as pagophagia, has been suggested to be the most specific for iron deficiency anemia.(9)

Iron deficiency without anaemia has been associated with:

  • weakness, fatigue, reduced exercise performance, difficulty in concentrating, and poor work productivity(10)
  • neurocognitive dysfunction including irritability(11)
  • fibromyalgia syndrome(12)
  • restless legs syndrome(13)
  • symptom persistence in patients treated for hypothyroidism(14)
  • poor neurodevelopmental outcomes in infants born to mothers with iron deficiency.(15)

Iron-deficiency anemia is confirmed by tests that include serum ferritin, serum iron level, serum transferrin, and total iron binding capacity. (16) A low serum ferritin is most commonly found. However, serum ferritin can be elevated by any type of chronic inflammation and thus is not consistently decreased in iron-deficiency anemia.(17) Serum iron levels may be measured, but serum iron concentration is not as reliable as the measurement of both serum iron and serum iron-binding protein levels. (18) The percentage of iron saturation (or transferrin saturation index or percent) can be measured by dividing the level of serum iron by total iron binding capacity and is a value that can help to confirm the diagnosis of iron-deficiency anemia; however, other conditions must also be considered, including other types of anemia.(19)

02

Conditions studied

  • Iron Deficiency, Anaemia in Children Type1DM

Browse trials for

03

In context

Iron Deficiencies

772 studies on the registry are indexed under Iron Deficiencies; 115 are open to participants now.

This study's planned enrollment of 141 is below the median of 200 across 151 observational studies indexed under Iron Deficiencies.

Browse Iron Deficiencies studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

cross sectional

Inclusion criteria

  • Primary School age children with type 1 diabetes from 6 years up to 12year .

Exclusion criteria

Exclusion Criteria:

  • 1-All children with type1 diabetes less than 6 years and above 12 years. 2-Exclude other autoimmune diseases associated with diabetes mellitus (hypothyroidism, Addison disease , pernicious anemia, Celiac disease).

3-Any condition affecting iron metabolism.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
141 participants (estimated)
Patient registry
No

Interventions

  • Dietary supplementIron

    observation effect of iron dificincy

06

What researchers measure

Primary outcomes

  1. detect the prevelance of anemic and non anemic iron deficiency in children with type 1 diabetes.

    detect the prevelance of anemic and non anemic iron deficiency in children with type 1 diabetes.

    Time frame: baseline

Secondary outcomes

  1. assess the impact of anemic and non anemic iron deficiency in children with type 1 diabetes on their general condition

    assess the impact of anemic and non anemic iron deficiency in children with type 1 diabetes on their general condition

    Time frame: baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rubenstein MD, Wall RT. Clinical use of beta-thromboglobulin levels in diagnosing and treating consumptive and immune thrombocytopenia. Am J Hematol. 1981 Jun;10(4):369-73. doi: 10.1002/ajh.2830100406. PubMed 6166192 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570837
Lead sponsor
Assiut University
Responsible party
Esraa Sayed Ahmed Sayed (Assistant Lecturer, Assiut University) — Principal investigator
First posted
Aug 26, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Jan 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Aug 26, 2024

Study contacts

Esraa sayed, MD
Contact
esrasayed567@gmail.com
01003908556
Shimaa kamal
Contact
01024982398

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion